ClinicalTrials.gg

Program

CHO cell

Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.

Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.

Furthest: phase 4, since Mar 28, 202229 company-led studies, 6 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Zhifei Biological Products121 open or runningphase 4since Mar 28, 2022Jun 16, 2020none ahead
Jiangsu Rec-Biotechnology50 open or runningphase 3since May 30, 2022Mar 19, 2021none ahead
MAXVAX Biotechnology Limited Liability54 open or runningphase 3since Jun 2, 2024Jun 2, 2024Dec 31, 2027phase 3 · NCT07293065
3SBio20 open or runningphase 3since Jan 13, 2022May 10, 2019none ahead
Guangzhou Patronus Biotech20 open or runningphase 3since Dec 23, 2022Dec 23, 2022none ahead
Sinopharm20 open or runningphase 2since Apr 24, 2021Apr 24, 2021none ahead
CSPC Pharmaceutical Group11 open or runningphase 2since Oct 19, 2026Oct 19, 2026Jul 31, 2027phase 2 · NCT07892989

Also a collaborator on its studies: yantai-patronus-biotech-co-ltd and iqvia-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since May 10, 2019.

  1. Nov 1, 20212 phase 3 studies in COVID-19Chongqing Zhifei Biological Products · NCT05107375, NCT05128643
  2. Nov 4, 2021Phase 2 study in COVID-19Chongqing Zhifei Biological Products · NCT05109598 · 400 enrolled · China
  3. Jan 13, 2022Phase 3 study in Kidney Failure, Chronic3SBio · NCT05211167 · 300 enrolled · China
  4. Mar 28, 2022Phase 4 study in COVID-19Chongqing Zhifei Biological Products · NCT05890521 · 100,000 planned · China
  5. Apr 11, 2022Phase 2 study in COVID-19Jiangsu Rec-Biotechnology · NCT05323435 · 300 enrolled · United Arab Emirates
  6. May 30, 2022Phase 3 study in COVID-19Jiangsu Rec-Biotechnology · NCT05398848 · 7,623 enrolled · Nepal, Russian Federation
  7. Oct 10, 2022No phase study in COVID-19Chongqing Zhifei Biological Products · NCT05574985 · 272 enrolled · China
  8. Dec 23, 2022Guangzhou Patronus Biotech's first studies: 2 phase 3 studies in COVID-19New to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT05664932, NCT05683600
  9. Jan 27, 2023Phase 1 study in Herpes ZosterJiangsu Rec-Biotechnology · NCT05769049 · 48 enrolled · Philippines
  10. Jun 2, 2024MAXVAX Biotechnology Limited Liability's first study: phase 3 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT06447779 · 25,000 enrolled · China
  11. Oct 22, 2024Phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT06654700 · 1,200 enrolled · China
  12. Nov 14, 20252 phase 3 studiesMAXVAX Biotechnology Limited Liability · NCT07272434, NCT07293065
  13. May 25, 2026No phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325 · 60 planned
  14. Oct 19, 2026CSPC Pharmaceutical Group's first study: phase 2 study in Herpes ZosterNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07892989 · 496 planned

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in Herpes ZosterCSPC Pharmaceutical Group · NCT07892989
  2. Dec 31, 2027Primary completion: phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT07293065
  3. Jun 30, 2028Primary completion: no phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07892989Herpes Zoster2Not yet recruitingCSPC Pharmaceutical GroupJul 31, 2027496
NCT07618325Respiratory Syncytial Virus (RSV)–Not yet recruitingMAXVAX Biotechnology Limited LiabilityJun 30, 202860
NCT07293065Herpes Zoster · China3Active, not recruitingMAXVAX Biotechnology Limited LiabilityDec 31, 202712,000
NCT07272434Respiratory Syncytial Virus (RSV) · China3RecruitingMAXVAX Biotechnology Limited LiabilityJul 31, 202625,000
NCT06654700Herpes Zoster · China3CompletedMAXVAX Biotechnology Limited LiabilityMay 9, 20251,200
NCT06447779Herpes Zoster · China3Active, not recruitingMAXVAX Biotechnology Limited LiabilityMar 29, 202625,000
NCT05769049Herpes Zoster · Philippines1CompletedJiangsu Rec-BiotechnologyDec 6, 202348
NCT05683600COVID-19 · China3TerminatedGuangzhou Patronus BiotechJul 12, 20233,000
NCT05664932COVID-19 · China3UNKNOWNGuangzhou Patronus BiotechJan 18, 20231,200
NCT05574985COVID-19 · China–CompletedChongqing Zhifei Biological ProductsOct 9, 2022272
NCT05398848COVID-19 · Nepal, Russian Federation3CompletedJiangsu Rec-BiotechnologySep 4, 20237,623
NCT05323435COVID-19 · United Arab Emirates2CompletedJiangsu Rec-BiotechnologyJul 5, 2022300
NCT05890521COVID-19 · China4RecruitingChongqing Zhifei Biological ProductsJun 16, 2022100,000
NCT05211167Kidney Failure, Chronic · China3UNKNOWN3SBioJun 30, 2023300
NCT05128643COVID-19 · China3UNKNOWNChongqing Zhifei Biological ProductsApr 12, 2022300
NCT05109598COVID-19 · China2CompletedChongqing Zhifei Biological ProductsFeb 14, 2022400
NCT05107375COVID-19 · China3CompletedChongqing Zhifei Biological ProductsMar 4, 2022299
NCT05084989COVID-19 · Philippines2CompletedJiangsu Rec-BiotechnologyAug 18, 2022948
NCT05091411COVID-19 · China3UNKNOWNChongqing Zhifei Biological ProductsNov 20211,680
NCT05089045COVID-19 · China–CompletedChongqing Zhifei Biological ProductsSep 16, 2021360
NCT05033847Coronavirus Infections · United Arab Emirates2UNKNOWNSinopharmNov 20231,800
NCT04961359Coronavirus Infections · China1CompletedChongqing Zhifei Biological ProductsDec 12, 202175
NCT04869592COVID-19 · China2CompletedSinopharmAug 29, 20233,100
NCT04818801COVID-19 · New ZealandEarly 1CompletedJiangsu Rec-BiotechnologyMay 5, 2022100
NCT04646590Prevention of COVID-19 · China, Ecuador, Indonesia and more3UNKNOWNChongqing Zhifei Biological ProductsNov 28, 202128,904
NCT04550351Coronavirus Infections · China1UNKNOWNChongqing Zhifei Biological ProductsDec 18, 202050
NCT04466085Coronavirus Infections · China2UNKNOWNChongqing Zhifei Biological ProductsOct 22, 2020900
NCT04445194Coronavirus Infections · China1UNKNOWNChongqing Zhifei Biological ProductsOct 22, 202050
NCT03950687Chronic Renal Failure With Hemodialysis · China2UNKNOWN3SBioJun 30, 2020150

How it is read

Names in the registry

  • “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
  • “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
  • “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
  • “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
  • “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
CHO cell (Chongqing Zhifei Biological Products): development program | ClinicalTrials.gg